BMY vs XPER · P/E 17, rev $24.46B vs rev $448.1M
Bristol-Myers Squibb Company (BMY) versus Xperi Corp (XPER) — a side-by-side from cached financials, not a winner call.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Chris Boerner.
Xperi Corp (XPER) is a software - application company listed on US.
Latest reported BMY revenue for 2026-06-30 was $24.46B. Net income was $5.99B. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Latest reported XPER revenue for 2025-12-31 was $448.1M. Net income was -$56.3M. Revenue was down 9.2% from 2024-12-31 to 2025-12-31. XPER currently screens at market cap $367.8M.
BMY currently screens at market cap $95.36B and trailing P/E 17.5. XPER currently screens at market cap $367.8M.
Not investment advice. Open the BMY and XPER stock pages for the full models.
Not investment advice.